Wall Street brokerages expect that ResMed Inc. (NYSE:RMD) will report $0.84 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for ResMed’s earnings, with estimates ranging from $0.80 to $0.88. ResMed posted earnings of $0.92 per share in the same quarter last year, which would indicate a negative year over year growth rate of 8.7%. The business is scheduled to announce its next earnings results after the market closes on Thursday, May 2nd.

According to Zacks, analysts expect that ResMed will report full year earnings of $3.55 per share for the current year, with EPS estimates ranging from $3.41 to $3.82. For the next financial year, analysts expect that the firm will post earnings of $3.85 per share, with EPS estimates ranging from $3.69 to $4.09. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow ResMed.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 24th. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The company had revenue of $651.10 million for the quarter, compared to analysts’ expectations of $676.77 million. ResMed had a net margin of 18.34% and a return on equity of 26.53%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Several research firms have recently weighed in on RMD. Deutsche Bank downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. JPMorgan Chase & Co. downgraded shares of ResMed from a “neutral” rating to an “underweight” rating and set a $99.60 target price on the stock. in a research report on Friday, January 25th. Goldman Sachs Group downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, January 25th. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “buy” rating and set a $116.00 target price on the stock in a research report on Monday, April 1st. Finally, ValuEngine cut shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday, April 4th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $110.33.

In other ResMed news, CEO Michael J. Farrell sold 6,651 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $100.82, for a total value of $670,553.82. Following the sale, the chief executive officer now owns 292,933 shares of the company’s stock, valued at approximately $29,533,505.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Robert Andrew Douglas sold 4,285 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $102.29, for a total transaction of $438,312.65. Following the completion of the sale, the insider now directly owns 48,604 shares in the company, valued at approximately $4,971,703.16. The disclosure for this sale can be found here. Insiders sold 76,759 shares of company stock valued at $7,723,835 over the last quarter. Corporate insiders own 1.24% of the company’s stock.

Several large investors have recently modified their holdings of RMD. Executive Wealth Management LLC acquired a new position in ResMed during the 4th quarter worth about $35,000. Parallel Advisors LLC lifted its position in ResMed by 143.0% during the 4th quarter. Parallel Advisors LLC now owns 328 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 193 shares during the period. Financial Gravity Companies Inc. acquired a new position in ResMed during the 4th quarter valued at about $34,000. Pinnacle Bank acquired a new position in ResMed during the 4th quarter valued at about $42,000. Finally, Financial Gravity Wealth Inc. acquired a new position in ResMed during the 1st quarter valued at about $51,000. Institutional investors own 68.12% of the company’s stock.

Shares of ResMed stock traded up $1.85 during trading on Tuesday, hitting $99.22. The stock had a trading volume of 822,578 shares, compared to its average volume of 766,042. The company has a market cap of $14.22 billion, a P/E ratio of 28.11, a price-to-earnings-growth ratio of 2.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.44 and a quick ratio of 1.76. ResMed has a 1 year low of $90.64 and a 1 year high of $118.50.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Read More: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on ResMed (RMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.